Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"Big pharma"”.
-
'Pyrates' of the Lyceum: Big Pharma, Patents, and Academic Freedom in Neoliberal Times
… this brave new world and the intellectual pyscho-pharmacology and ideology of neoliberalism.
-
Assessing decision inputs in drug development between small, early stage companies and big pharma : is there is a difference?
… challenge facing large, publicly traded pharmaceutical companies, collectively referred to as "Big Pharma," is well known. The unprecedented success Big Pharma achieved over the past few decades in commercializing blockbuster products means that it is now faced with near-term patent …
-
The role of finance and intangibles in the financialised pharmaceutical sector
… huge breakthroughs in high-tech sectors like pharmaceuticals. Meanwhile, these same sectors face intensified public scrutiny, over issues ranging from monopolisation to pricing, product safety, and more. The nature and institutional context of the contemporary pharmaceutical sector affords …
-
Patents and licensing and the commercialization of academic biomedical research
… research: universities, biotech firms, and big pharma. The Recombinant Capital database provided access to contracts for biomedical technology licensed from academe to biotech, and also subsequent contracts that included that same technology from biotech to big pharma. These two contracts …
-
What future physicians want : a comparative analysis of the perception of medical students and pharmaceutical industry executives regarding the future of pharmaceutical sales
The leading publicly traded pharmaceutical companies ("Big Pharma) in the US are facing a commercial crisis - their sales structure collectively consisting of more than 100,000 pharmaceutical sales representatives, originally setup to launch blockbusters, is suffering as a result of shrinking …
-
Increasing access to medicines in Southern Africa
… Our research, in partnership with one of the Big Pharma companies, addressed two intertwined yet distinct research areas. On one hand, we evaluated how price reductions (i.e. subsidy) offered by our partner company to the distributor translated down the value chain. On the other, we analyzed …
-
Unlocking value in healthcare delivery channels
Pharmaceutical supply chains are strictly regulated and work within unique constraints. Traditionally, innovator companies that are manufacturing the product have no direct interaction with the end users (treatment sites or individual patients); rather, over 90% of the orders go through …
-
Trends in Pharmaceutical Product Development 2000-2010
… the study was to find out, whether any trends in pharmaceutical product development could be detected from data on granted marketing authorisations. Also the lifecycle management approaches the major pharmaceutical companies use to protect their blockbuster products from generic competition and to …
-
Beyond the Legalization of Marijuana: Economics of Marijuana as a Drug and Herbal Supplement
… they have not critically analyzed how the pharmaceutical industry might react when synthetic cannabinoid compounds could be incorporated into new products. I argue that when marijuana is federally legal, there will be two independent market developments in: i) the cannabis market, which …